期刊文献+

γδT淋巴细胞及其亚型在毒性弥漫性甲状腺肿中的分布研究

Distribution of γδT lymphocytes and their subtypes in toxic diffuse goiter
下载PDF
导出
摘要 目的研究γδT淋巴细胞及其亚型在毒性弥漫性甲状腺肿(GD)中的分布并探讨γδT淋巴细胞在GD免疫学发病机制中的作用。方法选取2022年6-12月上海市嘉定区中心医院内分泌门诊确诊的GD患者59例作为GD组,另选择同期65例健康志愿者作为对照组。检测两组相关甲状腺指标[包括游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TG-Ab)、抗促甲状腺激素受体抗体(TRAb)],采用流式细胞术检测两组外周血中γδT淋巴细胞及其亚型的比例,分析γδT淋巴细胞表面活化分子CD69、HLA-DR及协同刺激分子CD40配体(CD40L)与诱导性共刺激分子(ICOS)的表达水平。结果GD组TSH水平低于对照组,FT3、FT4、TPOAb、TG-Ab、TRAb水平均高于对照组,差异均有统计学意义(P<0.05)。两组γδT淋巴细胞比例比较,差异无统计学意义(P>0.05);GD组Vδ1γδT淋巴细胞比例高于对照组,Vδ2γδT淋巴细胞比例低于对照组,差异均有统计学意义(P<0.05)。GD组γδT淋巴细胞表面活化分子CD69、HLA-DR表达水平及协同刺激分子CD40L、ICOS的表达水平均明显高于对照组,差异均有统计学意义(P<0.05)。结论GD患者外周血γδT淋巴细胞亚型改变表现为Vδ1γδT淋巴细胞比例上调与Vδ2γδT淋巴细胞比例下调,γδT淋巴细胞功能活化并表达协同刺激分子CD40L、ICOS可能是促进GD产生自身抗体及自身体液免疫应答的重要病理机制。 Objective To investigate the distribution of γδT lymphocytes and their subtypes in toxic diffuse goiter(GD),and to explore the role of γδT lymphocytes in the immunological pathogenesis of GD.Methods A total of 59 GD patients diagnosed in the endocrinology clinic of the Central Hospital of Shanghai Jiading District from June 2022 to December 2022 were selected as the GD group,and 65 healthy volunteers in the same period were selected as the control group.Two groups of relevant thyroid indicators[including free triiodothyronine(FT3),free thyroxine(FT4),thyrotropin(TSH),thyroid peroxidase antibody(TPOAb),thyroglobulin antibody(TG-Ab),anti-thyrotropin receptor antibody(TRAb)] were detected.Flow cytometry was used to detect the proportion of γδT lymphocytes and their subtypes in peripheral blood of the two groups,and the expression levels of activating molecules CD69,HLA-DR,co-stimulatory molecules CD40 ligand(CD40L) and inducible co-stimulator molecule(ICOS) on the surface of γδT lymphocytes were analyzed.Results The level of TSH in the GD group was lower than that in the control group,and the levels of FT3,FT4,TPOAb,TG-Ab and TRAb were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the proportion of γδT lymphocytes between the two groups(P>0.05).The GD group had a significantly higher proportion of Vδ1γδT lymphocytes and a significantly lower proportion of Vδ2γδT lymphocytes than the control group(P<0.05).The expression levels of activating molecules CD69 and HLA-DR and costimulatory molecules CD40L and ICOS on γδT lymphocytes in GD group were significantly higher than those in control group(P<0.05).Conclusion The proportion of Vδ1γδT cells is up-regulated and Vδ2γδT cells is down-regulated in GD patients.The activation of γδT cells and the expression of costimulatory molecules CD40L and ICOS may be an important pathological mechanism to promote the production of autoantibodies and autoimmune humoral immune response in GD.
作者 王姜琳 梁冬雨 汪国庆 赵江峰 汤明明 杨慧健 WANG Jianglin;LIANG Dongyu;WANG Guoqing;ZHAO Jiangfeng;TANG Mingming;YANG Huijian(Department of Clinical Laboratory,Central Hospital of Shanghai Jiading District,Shanghai 201800,China;Department of Central Laboratory,Central Hospital of Shanghai Jiading District,Shanghai 201800,China;Department of Rheumatology Laboratory,Central Hospital of Jiading District,Shanghai 201800,China;Department of Endocrinology,Central Hospital of Jiading District,Shanghai 201800,China;Department of Clinical Laboratory,Shanghai Zhongye Hospital,Shanghai 200941,China)
出处 《检验医学与临床》 2024年第5期592-595,602,共5页 Laboratory Medicine and Clinic
基金 上海市嘉定区科学委员会基金项目(JDKW-2019-W24) 上海市卫生和计划生育委员会青年基金项目(20184Y0087)。
关键词 毒性弥漫性甲状腺肿 ΓΔT淋巴细胞 表面活化分子 协同刺激分子 诱导性共刺激分子 toxic diffuse goiter γδT lymphocyte surface activated molecule costimulatory molecule inducible co-stimulator molecule
  • 相关文献

参考文献12

二级参考文献115

  • 1陈勇,吕合作,李柏青,王伟,张海峰.纯化的结核杆菌多肽抗原刺激人γδT细胞的效应分析[J].中国免疫学杂志,2004,20(10):661-664. 被引量:9
  • 2覃汉军,张叔人.免疫突触与T细胞活化关系的研究[J].现代免疫学,2005,25(5):426-429. 被引量:3
  • 3The National Academy of Clinical Biochemistry (NACB).Laboratory Medicine Practice Guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid ,2003,13 : 3- 126.
  • 4The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2006,16 : 109-141.
  • 5Teng WP, Shah ZY, Teng XC, et al. Effect of iodine intake on thyroid disease in China. N Engl J Med, 2006, 354:2783-2793.
  • 6Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA, 1995, 273:808-812.
  • 7邢家骝.131I治疗甲状腺功能亢进.邢家骝.131I治疗甲状腺疾病.北京:人民卫生出版社,2002.152-196.
  • 8中华医学会核医学分会.甲状腺疾病的131I治疗.中华医学会.临床技术操作规范·核医学分册.北京:人民军医出版社,2004.175-177.
  • 9中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:823
  • 10Caccamo N, Battistini L, Bonneville M, et al. CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B ceils for antibody production [ J ]. J Immunol, 2006, 177(8) : 5290 -5295.

共引文献222

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部